A Look at the Life and Career of Dr. Lindsay Rosenwald
As a major player in the biotechnology sector, Dr. Lindsay Rosenwald is known as a pacesetter for the latest innovations in the healthcare and biotechnology industry. His portfolio of companies ranges from promising drug companies to research companies working on exciting new cancer drugs.
As a well known Wall Street venture capitalist, Dr. Lindsay Rosenwald possesses the pioneer spirit when searching for fresh, new investment opportunities. He has a strong reputation and almost two decades of experience as a venture capitalist investing in research and development, biotechnology and healthcare. Over the years, Dr. Rosenwald has made great contributions to the world of healthcare research and investing.
Over the course of his impressive 20 year career as an investor and hedge fund manager, Dr. Lindsay A. Rosenwald has been responsible for establishing and re-capitalizing numerous private and public companies within the sectors of biotechnology and life sciences. He has built many profitable, productive relationships over the years with these companies and their founders.
As one of the directors of the Republican Jewish Coalition, Dr. Lindsay Rosenwald also serves as president of Paramount Group Inc., a real estate investment and management firm. He considers one of his greatest accomplishments to be the founding of OpusPoint Partners, LLC located in New York. This relatively new company is committed to identifying and investing in various breakthroughs in healthcare and life science.
Dr. Rosenwald recently negotiated the sale of Cougar Biotechnology Inc. to Johnson & Johnson for nearly $1 billion dollars. Cougar Biotechnology is a development stage biopharmaceutical company that focuses on oncology. The company is currently conducting Phase III trials for a first-in-class compound for late-stage prostate cancer. The drug is called abiraterone acetate.
After only a few years in business, OpusPoint Partners LLC has already made great strides both in the world of investing and medicine. Dr. Lindsay Rosenwald believes that OpusPoint will continue to seek investment opportunities in cutting edge R&D and healthcare companies, searching for start-up businesses and publicly traded companies that will improve the quality of life.
Dr. Rosenwald and the team at OpusPoint Partners utilize their strengths and many years of experience to lead the way in the world of biotechnology and investing. Known as a visionary in these fields, Dr. Rosenwald was the first to invest in a new drug for obesity released in the U.S. market. He also participated in investing in the very first public gene therapy company, and often sees potential for medical breakthroughs that others might miss.
Dr. Lindsay Rosenwald is a graduate of Penn State University with a degree in finance. He received his MD from the Temple University School of Medicine completing his internship at Abington Medical Hospital.